Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM0YCPL)

Drug Name
Bemcentinib Drug Info
Synonyms
R428; 1037624-75-1; BGB324; R-428; BGB-324; UNII-0ICW2LX8AS; (S)-1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine; CHEMBL3809489; SYN1131; CS-1046; HY-15150; QC-11751; R 428; W-5845; Bemcentinib [USAN]; R428 (BGB324); Bemcentinib (USAN/INN); BemcentinibR428BGB324); SCHEMBL1639904; GTPL10478; BGB 324; DTXSID70673109; 1-(6,7-dihydro-5H-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-N-[(7S)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine; AMY16774; BCP21180; C30H34N8; EX-A1720; SYN-1131; BDBM50172079; NSC824183; s2841; WHO 10631; ZINC51951669; AKOS032947237; ACN-037541; DB12411; NSC-824183; SB16614; NCGC00386665-07; 1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N~3~-[(7S)-7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]-1H-1,2,4-triazole-3,5-diamine; 1H-1,2,4-Triazole-3,5-diamine, 1-(6,7-dihydro-5H-benzo(6,7)cyclohepta(1,2-C)pyridazin-3-yl)-N3-((7S)-6,7,8,9-tetrahydro-7-(1-pyrrolidinyl)-5H-benzocyclohepten-2-yl)-; AC-28444; AS-16270; KB-80319; D11438; Q27236818; BGB324; BGB-324; BGB 324; R 428; R-428; Bemcentinib; 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(S)-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-diamine
Cross-matching ID
PubChem CID
46215462
ChEBI ID
CHEMBL3809489
CAS Number
CAS 1037624-75-1
TTD Drug ID
D0U8XE

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid biosynthesis 2.62 0.00e+0 19/20 (95%) SQLE;MSMO1;DHCR7;...
Terpenoid backbone biosynthesis 2.32 0.00e+0 18/22 (81.82%) HMGCS1;IDI1;ACAT2;...
Ferroptosis 2.16 0.00e+0 36/41 (87.8%) SLC7A11;FTH1;ACSL3;...
Lysosome 2.00 3.01e-3 115/128 (89.84%) FUCA1;ASAH1;ACP5;...
PPAR signaling pathway 1.99 4.81e-3 66/74 (89.19%) SCD;HMGCS1;PCK2;...
Valine, leucine and isoleucine degradation 1.96 6.01e-3 42/48 (87.5%) HMGCS1;ACAT2;HMGCS2;...
Synthesis and degradation of ketone bodies 1.94 5.15e-3 9/10 (90%) HMGCS1;ACAT2;HMGCS2
Biosynthesis of unsaturated fatty acids 1.94 4.51e-3 21/27 (77.78%) SCD;ELOVL6;HACD1;...
Pentose phosphate pathway 1.92 4.01e-3 25/30 (83.33%) PGD;ALDOC;G6PD;...
AMPK signaling pathway 1.83 1.32e-2 106/120 (88.33%) SCD;PCK2;HMGCR;...
Other glycan degradation 1.83 1.31e-2 13/18 (72.22%) FUCA1;NEU1;AGA;...
Citrate cycle (TCA cycle) 1.83 1.30e-2 30/30 (100%) IDH1;PCK2;ACLY;...
Insulin resistance 1.82 1.20e-2 96/108 (88.89%) PCK2;TRIB3;IRS2;...
Tryptophan metabolism 1.80 1.37e-2 35/42 (83.33%) ACAT2;KYNU;CYP1B1;...
Steroid hormone biosynthesis 1.76 2.16e-2 43/61 (70.49%) AKR1C3;AKR1C2;AKR1C1;...
Nicotinate and nicotinamide metabolism 1.75 2.18e-2 25/35 (71.43%) QPRT;NADSYN1;NMNAT2;...
Glycolysis / Gluconeogenesis 1.72 3.33e-2 56/67 (83.58%) PCK2;ALDH3A1;ALDOC;...
Pyruvate metabolism 1.70 4.08e-2 41/47 (87.23%) PCK2;ACAT2;ME1;...
Viral myocarditis 1.69 4.24e-2 53/60 (88.33%) CASP8;HLA-DQB1;HLA-DPB1;...
Fructose and mannose metabolism 1.69 4.09e-2 30/33 (90.91%) ALDOC;AKR1B10;SORD;...
Fatty acid biosynthesis 1.68 4.30e-2 16/18 (88.89%) ACSL3;FASN;ACACA;...
Glyoxylate and dicarboxylate metabolism 1.68 4.21e-2 23/30 (76.67%) ACAT2;SHMT2;PCCA;...
Allograft rejection 1.68 4.13e-2 32/38 (84.21%) HLA-DQB1;HLA-DPB1;HLA-C;...
Graft-versus-host disease 1.66 4.36e-2 32/42 (76.19%) HLA-DQB1;HLA-DPB1;HLA-C;...
Riboflavin metabolism 1.66 4.38e-2 7/8 (87.5%) ACP5;BLVRB;RFK;...
Mucin type O-glycan biosynthesis 1.65 4.39e-2 20/36 (55.56%) GALNT12;GALNT14;GALNT7;...
Propanoate metabolism 1.65 4.28e-2 30/34 (88.24%) ACAT2;ACACA;PCCA;...
Pantothenate and CoA biosynthesis 1.63 4.77e-2 14/21 (66.67%) PANK3;ALDH1B1;ALDH2;...
Protein digestion and absorption -1.67 4.73e-2 78/103 (75.73%) KCNN4;ATP1B2;COL2A1;...
Hippo signaling pathway -1.68 4.73e-2 120/186 (64.52%) PAK1;BIRC3;BIRC5;...
Complement and coagulation cascades -1.75 3.16e-2 76/85 (89.41%) CFH;BDKRB1;ITGAM;...
Proteasome -1.83 1.84e-2 44/46 (95.65%) PSMA6;PSMC1;PSME2;...
Focal adhesion -1.89 3.95e-3 180/201 (89.55%) CRK;GSK3B;RASGRF1;...
ECM-receptor interaction -2.22 0.00e+0 80/88 (90.91%) LAMC3;LAMA2;TNN;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 24H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 24H
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H